Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cancer Research

• Publication date

  2011-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-11-1227PMID 21795476PMCID PMC3166628
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Poly(ADP-ribose) polymerase and XPF–ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells

  2011cited by this paper
• Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells

  2010cited by this paper
• Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity

  2010cited by this paper
• A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors.

  2010cited by this paper
• Clinical Cancer esearch cer Therapy : Preclinical elopment of a Validated Immunofluorescence Assay γ H 2 AX as a Pharmacodynamic Marker of R oisomerase I Inhibitor Activity

  2010cited by this paper
• Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.

  2009cited by this paper
• Liquid Chromatographic Determination of NSC 737664 (ABT-888: An Inhibitor of Poly(ADP-ribose) Polymerase (PARP)) in Plasma and Urine in a Phase 0 Clinical Trial

  2008cited by this paper
• Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts

  2008cited by this paper
• γH2AX and cancer

  2008cited by this paper
• ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

  2007cited by this paper
• Repair of topoisomerase I-mediated DNA damage.

  2006cited by this paper
• Topoisomerase I inhibitors: camptothecins and beyond

  2006cited by this paper
• First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM).

  2006cited by this paper
• Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors

  2005cited by this paper
• Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.

  2005cited by this paper
• The Novel Poly(ADP-Ribose) Polymerase Inhibitor, AG14361, Sensitizes Cells to Topoisomerase I Poisons by Increasing the Persistence of DNA Strand Breaks

  2005cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• The PARP superfamily

  2004cited by this paper
• A Novel Methionine-Based Signaling Mechanism Regulating the Expression of Thymidylate Synthase

  2003cited by this paper
• Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.

  2003cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro

  1997cited by this paper
• A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.

  1997cited by this paper
• Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.

  1997cited by this paper
• High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma.

  1990cited by this paper

• Regulatory networks of HIFs in tumor-infiltrating immune cells: From molecular mechanisms to therapeutic implications (Review)

  2026cites this paper
• Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling

  2025cites this paper
• Fuzzy-DDI: A robust fuzzy logic query model for complex drug-drug interaction prediction

  2025cites this paper
• Targeting DNA Topoisomerase I for the Treatment of Cancer: Past, Present and Future.

  2025cites this paper
• Interactions Between Non-Coding RNAs and HIF-1alpha in the Context of Colorectal Cancer

  2025cites this paper
• Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review

  2025cites this paper
• PARP-1 and PARP-2 in B-cell Lymphoma: Pathogenic Roles and Therapeutic Implications.

  2025cites this paper
• LRG1-Targeted Camptothecin Nanomicelles with Simultaneous Delivery of Olaparib for Enhanced Colorectal Cancer Chemotherapy.

  2025cites this paper
• PARP1-dependent DNA-protein crosslink repair

  2024cites this paper
• Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

  2024cites this paper
• TransFOL: A Logical Query Model for Complex Relational Reasoning in Drug-Drug Interaction

  2024cites this paper
• Targeting the DNA damage response in hematological malignancies

  2024cites this paper
• Novel inhibitors of PARP1 and PARP14: design, synthesis, and potentiation of cisplatin efficacy in cancer.

  2024cites this paper
• Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2

  2024cites this paper
• Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial.

  2023cites this paper
• Design, synthesis and development of a dual inhibitor of Topoisomerase 1 and poly (ADP-ribose) polymerase 1 for efficient killing of cancer cells.

  2023cites this paper
• Current and Emerging Role of Antibody-Drug Conjugates in HER2-Negative Breast Cancer.

  2023cites this paper
• PARP inhibitors combined with radiotherapy: are we ready?

  2023cites this paper
• FF-10850, a Novel Liposomal Topotecan Achieves Superior Antitumor Activity via Macrophage- and Ammonia-Mediated Payload Release in the Tumor Microenvironment

  2023cites this paper
• A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors.

  2023cites this paper
• Evolution of the Development of PARP Inhibitors.

  2023cites this paper
• Potential agnostic role of BRCA alterations in patients with several solid tumors: one for all, all for one?

  2023cites this paper
• PARP Inhibitors in Colorectal Malignancies: A 2023 Update.

  2023cites this paper
• Case Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy

  2023cites this paper
• Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer

  2023cites this paper
• A Multi-Site Phase I Trial of Veliparib with Standard Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)

  2023cites this paper
• Exploiting DNA Replication Stress as a Therapeutic Strategy for Breast Cancer

  2022cites this paper
• Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers

  2022cites this paper
• Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

  2022cites this paper
• Recent advances in structural types and medicinal chemistry of PARP-1 inhibitors

  2022cites this paper
• ROADMAPS: An Online Database of Response Data, Dosing Regimens, and Toxicities of Approved Oncology Drugs as Single Agents to Guide Preclinical In Vivo Studies

  2022influential citation
• Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer

  2022cites this paper
• Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer

  2022cites this paper
• Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer

  2021cites this paper
• Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force

  2021cites this paper
• The Novel Dual Topoisomerase Inhibitor P8-D6 Shows Anti-myeloma Activity In Vitro and In Vivo

  2021cites this paper
• Perspectives on PARP Inhibitor Combinations for Ovarian Cancer

  2021cites this paper
• PARP Inhibitors and Haematological Malignancies—Friend or Foe?

  2021cites this paper
• Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor.

  2021cites this paper
• AR-V7 Protein Expression in Circulating Tumour Cells Is Not Predictive of Treatment Response in mCRPC

  2020cites this paper
• Development of new medical treatment for epithelial ovarian cancer recurrence.

  2020cites this paper
• Highlights in metastatic breast cancer from the European Society for Medical Oncology Virtual Congress 2020.

  2020cites this paper
• Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences.

  2020cites this paper
• An assessment of poly (ADP‐ribose) polymerase‐1 role in normal and cancer cells

  2020cites this paper
• The DNA Damage Response pathway as a land of therapeutic opportunities for colorectal cancer.

  2020cites this paper
• Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up

  2020cites this paper
• Design, Synthesis, and Anticancer Potential of the Enzyme (PARP-1) Inhibitor with Computational Studies of New Triazole, Thiazolidinone, - Thieno [2, 3-d] Pyrimidinones

  2020cites this paper
• Synthesis and biological evaluation of piperidyl benzimidazole carboxamide derivatives as potent PARP-1 inhibitors and antitumor agents

  2020cites this paper
• Therapeutic Targeting of Cancer Cells

  2020cites this paper
• GSK3β Inhibition Synergizes with PARP Inhibitors through the Induction of Homologous Recombination Deficiency in Colorectal Cancer

  2020cites this paper
• Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?

  2020cites this paper
• PARP Inhibition to Enhance Response to Chemotherapy

  2019cites this paper
• Topoisomerases and cancer chemotherapy: recent advances and unanswered questions

  2019cites this paper
• Recent Advances in Use of Topoisomerase Inhibitors in Combination Cancer Therapy.

  2019cites this paper
• Poly (ADP-ribose) polymerase (PARP) inhibitors as chemosensitizing compounds for the treatment of drug resistant cancers

  2019cites this paper
• Novel Therapeutic Approaches and Targets for Ovarian Cancer

  2019cites this paper
• Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities.

  2019cites this paper
• Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review.

  2019cites this paper
• Genotoxic effects of topoisomerase poisoning and PARP inhibition on zebrafish embryos.

  2019cites this paper
• Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach

  2019cites this paper
• Phase 0 Clinical Trial Strategies for the Neurosurgical Oncologist

  2019cites this paper
• Genomics and molecular mechanisms of high grade serous ovarian cancer: the 12th Biennial Rivkin Center Ovarian Cancer Research Symposium

  2019cites this paper
• Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies

  2019cites this paper
• Targeting the CINful genome: Strategies to overcome tumor heterogeneity.

  2019cites this paper
• The DNA Damaging Revolution: PARP Inhibitors and Beyond.

  2019cites this paper
• A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer

  2019cites this paper
• PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”

  2019cites this paper
• PARP Trapping Beyond Homologous Recombination and Platinum Sensitivity in Cancers

  2019cites this paper
• DNA Double Strand Break Repair - Related Synthetic Lethality.

  2019cites this paper
• Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors

  2019cites this paper
• Challenges and Opportunities for Childhood Cancer Drug Development

  2019cites this paper
• Targeting Topoisomerase I in the Era of Precision Medicine

  2019influential citation
• Veliparib: a new therapeutic option in ovarian cancer?

  2019cites this paper
• Investigation into the role of HER2 receptor signalling in Hypoxia-inducible Factor Regulation in breast cancer

  2018cites this paper
• QSAR Model Generation of Phthalazinones as Poly (ADP-Ribose) Polymerase Inhibitors by the Genetic Algorithm and Multiple Linear Regression (GA-MLR) Method: A Ligand-Based Approach for Cancer Drug Design

  2018cites this paper
• Current perspectives on genotype classification and individualized drug targeting in triple-negative breast cancer

  2018cites this paper
• Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going

  2018cites this paper
• Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild‐type BRCA pancreatic ductal adenocarcinoma

  2018cites this paper
• PARP inhibitors and breast cancer: highlights and hang-ups

  2018cites this paper
• Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent

  2018cites this paper
• Population pharmacokinetics and exposure–response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias

  2018cites this paper
• High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects

  2018cites this paper
• PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow

  2018cites this paper
• Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status.

  2018cites this paper
• PARP inhibition in platinum‐based chemotherapy: Chemopotentiation and neuroprotection

  2018cites this paper
• Currently Approved Poly (Adenosine Diphosphate-Ribose) Inhibitors in Ovarian Cancer: Current Status and Future Directions

  2018cites this paper
• Hereditary Breast Cancer

  2018cites this paper
• Targeting DNA Damage Response Pathways in Cancer

  2017cites this paper
• Colorectal Cancer Chemotherapy: The Evolution of Treatment and New Approaches.

  2017cites this paper
• Development of PARP inhibitors in gynecological malignancies.

  2017cites this paper
• The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells

  2017cites this paper
• Poly(ADP-Ribose) polymerase 1: a therapeutic hope in gynecologic cancers.

  2017cites this paper
• PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models

  2017cites this paper
• PARP inhibitors as precision medicine for cancer treatment

  2017cites this paper
• Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies

  2017cites this paper
• Investigating the role of Tyrosyl-DNA Phosphodiesterase 1 in nuclear and mitochondrial DNA repair

  2017cites this paper
• Reprogramming of the Tumor in the Hypoxic Niche: The Emerging Concept and Associated Therapeutic Strategies.

  2017cites this paper
• Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors.

  2017cites this paper
• PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs

  2017cites this paper
• PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

  2017cites this paper